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Abstract
Introduction: Residual subclinical synovitis can still be present in joints of rheumatoid arthritis (RA) patients despite
clinical remission and has been linked to ongoing radiological damage. The aim of the present study was to assess
subclinical synovitis by positron emission tomography (PET; macrophage tracer 11C-(R)-PK11195) in early RA patients
with minimal disease activity without clinically apparent synovitis (MDA); and its relationship with clinical outcome
and magnetic resonance imaging (MRI), respectively.
Methods: Baseline PET and MRI of hands/wrists were performed in 25 early MDA RA patients (DAS 44 < 1.6; no
tender/swollen joints) on combined DMARD therapy. PET tracer uptake (semi-quantitative score: 0–3) and MRI
synovitis and bone marrow edema (OMERACT RAMRIS) were assessed in MCP, PIP and wrist joints (22 joints/patient;
cumulative score).
Results: Eleven of 25 patients (44 %) showed enhanced tracer uptake in≥ 1 joint. Fourteen of these 25 (56 %)
patients developed a flare within 1 year: 8/11 (73 %) with a positive, and 6/14 (43 %) with a negative PET. In the
latter, in 5/6 patients flare was located outside the scan region. Median cumulative PET scores of patients with a
subsequent flare in the hands or wrists were significantly higher than those of patients without a flare (1.5 [IQR 0.8–5.3]
vs 0.0 [IQR 0.0–1.0], p = 0.04); significance was lost when all flares were considered (1.0 [IQR 0.0–4.0] vs 0.0 [IQR 0.0–1.0],
p = 0.10). No difference in cumulative MRI scores was observed between both groups.
Conclusions: Positive PET scans were found in almost half of early RA patients with MDA. Patients with a subsequent
flare in hand or wrist had higher cumulative PET scores but not MRI scores, suggesting that subclinical arthritis on PET
may predict clinical flare in follow-up.
Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory
disease that affects the joints. RA patients with high levels
of disease activity have worse clinical and radiological
outcomes than patients with minimal disease activity
(MDA) or patients in remission [1]. A state of true remis-
sion [2] is the main therapeutic objective of RA, and
certainly MDA [3] is becoming a more realistic goal
owing to intensified treatment with disease-modifying
anti-rheumatic drugs (DMARDs) [4]. We showed treat-
to-target regimens such as Combinatietherapie bij Reu-
matoïde Artritis (COBRA) or COBRA-light therapy—
comprising methotrexate (MTX) with or without sulfa-
salazine (SSZ) and high-dose or moderate-dose prednisol-
one respectively—to be effective in establishing MDA or
remission, at least partly by their target design in which
patients without a favorable response (clinical remission)
are offered other, probably more powerful, antirheumatic
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drugs [5, 6]. In addition, once drug-induced remission has
been achieved, prevention of structural damage is most
likely if remission is maintained [7]. Unfortunately, recur-
rent flares are common in RA patients [8–10]. Further-
more, there is evidence that progression of joint damage
may proceed despite the absence of clinical synovitis—that
is, in patients with MDA or in remission—presumably
due to the presence of subclinical disease activity [11, 12].
In contrast to conventional X-ray scanning, advanced
imaging techniques such as magnetic resonance imaging
(MRI), ultrasound (US), and positron emission tomog-
raphy (PET) allow detection and quantification of sub-
clinical synovitis [13–16]. MRI and US abnormalities are
associated with future radiological damage and flaring in
RA (remission) patients [12, 15–20], but this association is
not very strong [21], leaving room for alternative imaging
techniques that could further contribute to specificity.
PET depicts biological targets and can be used for
sensitive detection of inflammation at molecular and
cellular levels. Macrophage-targeting PET tracers, such
as 11C-(R)-PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-
methylpropyl)-3-isoquinoline carboxamide), can visualize
inflammatory processes. We have recently shown that
PET and macrophage targeting is a promising technique
for identification of longstanding RA patients with signs
of subclinical synovitis related to short-term flare [15], but
such studies have not yet been conducted in early RA
patients.
We explored whether 11C-(R)-PK11195 PET could de-
pict residual disease activity in early RA patients that
achieved a state of MDA with intensive DMARD combin-
ation treatment. Patients were also followed to determine
whether such residual disease activity could be linked to
development of flare. Finally, PET results were compared
with results from contrast-enhanced MRI.
Methods
Patients and study protocol
Patients who were diagnosed with RA (according to
the 1987 American College of Rheumatology (ACR) cri-
teria, mean (interquartile range (IQR)) disease duration
9.0 (7.0-15.0) months) years) by rheumatologists at the
VU University Medical Center or Jan van Breemen Re-
search institute | Reade were treated according to an in-
tensive regimen in a treat-to-target design, with either
COBRA (MTX, SSZ, and initially high-dose prednisone
60 mg per day) or COBRA-light therapy (with MTX up to
25 mg per week and prednisone initially 30 mg per day),
in which the therapeutic regimens have recently been
shown to be equally effective [5, 6]. Patients were con-
secutively asked to participate in the current PET substudy
if they were classified as having “minimal disease activity
without apparent synovitis” (MDA), which was defined as:
Disease Activity Score (DAS) in 44 joints <1.6 (which
conforms with the outcome definitions of the COBRA-
light trial); no tender joints according to the Ritchie ar-
ticular index (53 joints); and no swollen joints according
to a swollen joint count (44 joints) as scored by a trained
research nurse (at T = 26, 32, 52, or 78 weeks of the
COBRA-light trial). Eligibility criteria for the trial can
be found in the trial report [5, 6]. Specific criteria for
exclusion from this study were the presence of a pace-
maker, use of a benzodiazepine agonist 10 days prior to
PET scanning, and previous exposure to radioactivity with
a yearly cumulative dose of ≥5 mSv. Patients were allowed
to continue with DMARD treatment (COBRA, n = 11;
COBRA-light, n = 14) according to the study trial proto-
col. High (spatial) resolution (R)-11C-PK11195 PET (n =
25) and contrast-enhanced MRI (n = 24) were performed
on both hands and wrists.
Clinical follow-up data up to 1 year from inclusion in
this study were retrieved from the trial dataset and
included the World Health Organization–International
League of Associations for Rheumatology (WHO-ILAR)
core set [22], including swollen joint count (44 joints),
level of erythrocyte sedimentation rate (ESR), C-reactive
protein (CRP) levels, and evaluation of patient and
physician global health score by a visual analog scale
(VAS, 0–100 mm).
Ethical approval was obtained from the ethics commit-
tee of the VU University Medical Center and informed
consent was given by all patients prior to inclusion.
Clinical outcome measures
Flare was defined as the occurrence of at least one swollen
joint during a 44-joint examination [23].
The time to follow-up and the number of visits were
dependent on the time point within the COBRA-light trial
at which patients were eligible for inclusion in the sub-
study. At least two visits were available for each patient at
a median of 9 (IQR 7–15) weeks and 24 (IQR 21–47)
weeks. An additional visit was available at 50 (IQR 47–54)
weeks and 72 (IQR 70–76) weeks for respectively 18 and
12 patients. For all patients, a visit approximately 52 weeks
after inclusion in this substudy (range 45–69 weeks) was
available. For investigation of the relationship between the
level of cumulative PET/MRI scores and development of
flare in time, the cumulative PET and MRI scores of
patients who developed a flare early (at 9 weeks, i.e., the
median of the first follow-up visit) were compared with
those of patients who developed a flare later during follow
up (at 24 weeks, i.e., the median of the second follow-up
visit).
PET protocol and data analysis
At baseline, a double-layer ECAT High Resolution Re-
search Tomograph (CTI/Siemens) performed the 11C-(R)-
PK11195 PET scan (total duration: 27 min) of the left and
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right metacarpophalangeal (MCP), proximal interphalan-
geal (PIP), and wrist joints (in total, 22 joints per patient)
as described previously [14, 15]. Final consensus scores
reached by the two observers (CJvdL and OSH), who were
blinded to clinical and MRI data, were the input for
analysis. Joint uptake and background uptake were semi-
quantitatively scored as 0 (absent), 1 (faint), 2 (moderate),
or 3 (intense) as described previously [14]. Final scores
were calculated per joint by subtracting background
scores from joint scores. Joints were considered positive if
they had a final score of at least “1”. This cutoff value was
chosen based on previous PET results for healthy controls,
which were all scored negative after correction for back-
ground (i.e., final score 0). Patients were classified as posi-
tive if they had at least one PET-positive joint. Per patient,
a cumulative PET score (range 0–66) was obtained by
summing final individual joint scores of both hands and
wrists.
MRI protocol and data analysis
A 1.5 T whole-body MR scanner (Siemens Sonata,
Erlangen, Germany) acquired images of both hand and
wrist joints according to OMERACT (Outcome Measures
in Rheumatology) guidelines [15, 24]. For MRI, the same
joints (all MCP, PIP, and both wrist joints) as for PET were
imaged and scored for the presence of synovitis and bone
marrow edema on a semi-quantitative 0–3 scale, accord-
ing to the OMERACT RA MRI Scoring (RAMRIS) system
[24]. Consequently, our scoring method included the vali-
dated RAMRIS score of the dominant hand, but was ex-
panded by additional scoring for synovitis and (proximal/
distal) bone marrow edema of MCP 1 and PIP 1–5 joints
of the dominant hand and similar joints of the nondomi-
nant hand. Joints were considered positive if synovitis or
bone edema were scored at least “1”. Patients were classi-
fied as positive if they had at least one positive joint. Two
observers (NA and CD) read all scans, blinded to clinical
and PET data, and blinded to sequence. If joint scores be-
tween observers diverged by ≥2 points, consensus was
reached in a separate scoring session. For all other joints,
the mean score of both observers was calculated and used
for analysis. Per patient, a cumulative MRI score (range
0–288) was calculated by summing all individual (mean)
synovitis plus bone marrow edema joint scores of both
hands and wrists.
Statistical analysis
The intraclass correlation coefficient (ICC) (95 % confi-
dence interval (CI)) between two observers was calculated
for both PET and MRI cumulative scores.
Differences in cumulative scores between groups with
versus without a flare were evaluated with Mann–Whit-
ney U tests. p <0.05 was regarded as statistically
significant.
Point estimates and distribution of data are reported
as median (IQR) or mean (standard deviation (SD)). All
statistical tests were performed with IBM SPSS statistics
20 (IBM Corp., Armonk, NY, USA).
Results
Baseline patient characteristics
Twenty-five RA patients with MDA were included in this
study. Patient characteristics are presented in Table 1. All
included patients had a DAS in 44 joints <1.6. At the time
of inclusion in the present study, the 2011 ACR/European
League Against Rheumatism (EULAR) Boolean remission
criteria were not yet published. In retrospect, 18/25 (72 %)
of patients fulfilled these criteria [25]. For all remaining
patients a VAS general health score >10 mm (range
21–77) was the failing criterion. There were no statis-
tically significant differences in patient characteristics
between patients with and without a flare (results not
shown).
Baseline PET evidence of subclinical inflammation
The reliability between both observers was good (ICC
0.78 (95 % CI 0.57–0.90)). Eleven of 25 patients (44 %)
were PET-positive (for a representative PET scan, see
Table 1 Patient characteristics
Baseline characteristic Value
Female 13 (52 %)
Age (years) 53 (13)
Disease duration (months) 9.0 (7.0–15.0)
ESR (mm/hour) 5.0 (2.0–7.5)
CRP (mg/L) 2.5 (1.0–5.0)
VAS general health (0–100 mm) 5.0 (1.0–24.5)
Tender joint count 0
Swollen joint count 0
DAS in 44 joints 0.7 (0.3)
2011 Boolean ACR/EULAR remission 18 (72 %)
ACPA-positive 18 (72 %)
RF-positive 16 (64 %)
Medication
MTX 12 (48 %)
MTX + SSZ 8 (32 %)
LFL 1 (4 %)
MTX + etanercept 2 (8 %)
MTX + SSZ + etanercept 2 (8 %)
Prednisolone (maximum 7.5 mg per day) 16 (64 %)
Data presented as number (%), mean (standard deviation), or median
(interquartile range). n = 25
ACR American College of Rheumatology; CRP C-reactive protein, DAS Disease
Activity Score, EULAR European League Against Rheumatism, LFL leflunomide,
MTX methotrexate, RF rheumatoid factor; SSZ sulfasalazine, VAS visual analog
scale
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Fig. 1), with median 0.0 (IQR 0.0–2.5) positive joints.
Median cumulative PET score was 0.0 (IQR 0–2.5, max-
imum 9). At the joint level, 32/548 (6 %) joints were
PET-positive. The most frequent positive PET score was
1; a score of 2 was found in one joint in each of 3/11
(27 %) positive PET scans, and no joints scored 3.
PET outcome related to development of flare
Fourteen of our patients (56 %) developed a flare within
1 year: this comprised eight of the 11 PET-positive pa-
tients and six of the 14 PET-negative patients. Six patients
flared in the hands or wrists (the scan region), and five
were PET-positive. Only one patient thus had a truly
“false-negative” PET in that the flare occurred within the
scan region showing no PET signal. The same pattern was
seen in the cumulative PET scores: median scores were
significantly higher in patients with a flare in the hands/
wrists (n = 6) than in patients without (n = 11): 1.5 (IQR
0.8–5.3) versus 0.0 (IQR 0.0–1.0), p = 0.04. Significance
was lost in the comparison of all patients with a flare
versus those without: median score 1.0 (IQR 0.0–4.0)
versus 0.0 (IQR 0.0–1.0)), p = 0.10 (Fig. 2, left panel).
Results were similar when the definition of flare was
modified to “the presence of two swollen joints”, instead
of one swollen joint (results not shown).
The relationship between time to clinical flare and the
PET result was investigated by comparing cumulative PET
scores from the first follow-up visit (median 9 weeks) with
those from the second follow-up visit (median 24 weeks).
There was a weak trend for an inverse association between
cumulative PET scores and time to clinical flare (1.50
(IQR 0.0–7.6) versus 0.0 (IQR 0.0–3.8), p = 0.23, respect-
ively; results not shown).
PET in relation to MRI
MRI scans of 24 patients were available for analysis. The
median time interval between PET and MRI was 5 days
(IQR 5–5). MRI for one patient failed due to movement
artifacts (PET for this patient was negative, flare was
observed at 53 weeks after inclusion). The interobserver
reliability was excellent with an ICC of 0.94 (95 % CI
0.87–0.97).
The median cumulative score of all MRI scans was 10
(IQR 6–14). All MRI scans were scored positive. There-
fore, all PET-positive patients (n = 11) also had positive
MRI results. Vice versa, 13/24 (54 %) patients with a
positive MRI scan had negative PET scans. Bone marrow
edema was observed in 11/24 (46 %) patients. No differ-
ence in median cumulative MRI scores was found
between patients with and without a flare (11.5 (IQR
4.5–16.0) versus 9.5 (IQR 6.5–13.0), p = 0.47) (Fig. 2
right panel), and also when the comparison was limited
to patients with flare in hands/wrists (p = 0.27). Median
cumulative MRI scores of patients with a flare at the first
follow-up visit (median 9 weeks; 4.0 (IQR 1.6–5.9)) were
not significantly different from those with a flare at
the second follow-up visit (median 24 weeks; 3.6 (IQR
1.0–4.3), p = 0.37) (results not shown).
Discussion
This novel study demonstrated enhanced uptake of the
macrophage PET tracer 11C-(R)-PK11195 in the hands
and/or wrists of almost one-half of a cohort of early RA
patients in MDA after intensive combined DMARD the-
rapy. Furthermore, significantly higher cumulative PET
scores were observed in the subset of patients that flared
in hands/wrists compared with those patients without a
flare. These results support our previous results with 11C-
(R)-PK11195 PET in treated RA patients with longstand-
ing disease [15], and suggest that subclinical macrophage
activity can be present in treated RA patients with cli-
nically quiescent disease, regardless of disease duration.
Because the presence of subclinical disease activity and
frequent flares have negative impact on clinical outcome
Fig. 1 11C-(R)-PK11195 PET scan. Coronal 11C-(R)-PK11195 PET scans of two RA patients without apparent synovitis. Enhanced uptake of the
macrophage-targeting PET tracer 11C-(R)-PK11195 is visible as black hotspots (arrows). Interosseus muscles and nailbeds show normal background
uptake
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and prognosis, our findings strengthen the case for add-
itional imaging to determine the prognosis of RA patients
with MDA without clinically apparent synovitis. It is
promising that PET could even distinguish between pa-
tients with and without a flare in a setting of optimal
suppression of disease activity in a treat-to-target study.
Our MRI results support the findings of several other
studies that report MRI synovitis and bone marrow
edema—both regarded as signs of disease activity—in up
to 96 % and 46 % of RA patients with MDA, respectively
[13, 26, 27]. MRI is claimed to be particularly useful in the
detection of subclinical disease activity because of its high
sensitivity, which enables depiction of subtle signs of
inflammation that may not be detected by clinical examin-
ation. However, some of these MRI abnormalities may
have no clinical relevance, resulting in a low specificity
and the need for cutoff levels of diagnostic significance of
MRI findings [21]. Our study suggests higher specificity
for macrophage-targeted PET both for dichotomous out-
come (PET and MRI positivity at a patient level: yes/no)
and for the cumulative score. The diagnostic test value of
PET could be further increased if the scan region was
expanded from the hands to the whole body, for which
the PET technique is particularly suited. This was demon-
strated in the current study by a significant improvement
in differences in cumulative PET scores between the flare
and no flare subgroups and an increase from 57 % to 89 %
in negative predictive value if only flare in joints within
the field of view of the PET scanner was taken into
account.
Unfortunately, our study data did not allow conclusions
with regard to PET and MRI findings in relation to radio-
logical outcome due to the very low rates of progression
overall as reported in the main study [6]. Another limita-
tion is the variation in follow-up intervals for patients,
a consequence of adding this study to a running trial.
Nevertheless, a minimum of two visits was available
for each patient. Future studies in larger study popula-
tions are warranted to further prove (validate) the clinical
value of 11C-(R)-PK11195 PET scanning as a predictive
tool for flare in RA before it can be implemented in clin-
ical practice.
Conclusions
This study suggests a potential role for macrophage PET
scanning, but not MRI, in early RA patients under inten-
sive treatment to detect subclinical synovitis that may
develop into a clinical flare.
Abbreviations
ACR: American College of Rheumatology; CI: Confidence interval;
COBRA: Combinatietherapie bij Reumatoïde Artritis; CRP: C-reactive protein;
DAS: Disease Activity Score; DMARD: Disease-modifying anti-rheumatic drug;
ESR: Erythrocyte sedimentation rate; EULAR: European League Against
Rheumatism; ICC: Intraclass correlation coefficient; IQR: Interquartile range;
MCP: Metacarpophalangeal; MDA: Minimal disease activity; MRI: Magnetic
resonance imaging; MTX: Methotrexate; PET: Positron emission tomography;
PIP: Proximal interphalangeal; RA: Rheumatoid arthritis; RAMRIS: RA MRI
Scoring; SD: Standard deviation; SSZ: Sulfasalazine; US: Ultrasound; VAS: Visual
analog scale; WHO–ILAR: World Health Organization–International League of
Associations for Rheumatology.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YYJG and MMtW made substantial contributions to acquisition, analysis, and
interpretation of the data and drafted the manuscript. DdU, NA, and CD
made substantial contributions to acquisition of the data and critically
revised the manuscript. AEV, CvK, OSH, MB, WFL, and CJvdL participated in
the design of the study, made substantial contributions to interpretation of
the data, and critically revised the manuscript. All authors read and approved
the final manuscript.
funding
This research was performed within the framework of project T1-106 of the
Dutch Top Institute group.
Fig. 2 Cumulative PET and MRI scores of patients with and without
a flare. Horizontal line, median. Scores expressed as a percentage of
the maximum possible score (PET, 66; MRI, 288). In patients with a
flare, open symbols indicate those with a flare outside the hand or
wrist. MRI magnetic resonance imaging, PET positron emission
tomography
Gent et al. Arthritis Research & Therapy  (2015) 17:266 Page 5 of 6
Author details
1Department of Rheumatology, VU University Medical Center, De Boelelaan
1117, PO Box 7057, Amsterdam 1081, HV, The Netherlands. 2Department of
Radiology & Nuclear Medicine, VU University Medical Center, De Boelelaan
1117, Amsterdam 1081, HV, The Netherlands. 3Department of Rheumatology,
Jan van Breemen Research Institute | Reade, Amsterdam, dr. Jan van
Breemenstraat 2, Amsterdam 1056, AB, The Netherlands. 4Department of
Clinical Epidemiology & Biostatistics, VU University Medical Center, De
Boelelaan 1117, Amsterdam 1081, HV, The Netherlands.
Received: 1 March 2015 Accepted: 1 September 2015
References
1. van Tuyl LH, Felson DT, Wells G, Smolen J, Zhang B, Boers M. Evidence for
predictive validity of remission on long-term outcome in rheumatoid
arthritis: a systematic review. Arthr Care Res (Hoboken). 2010;62:108–7.
2. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al.
American College of Rheumatology/European League against Rheumatism
provisional definition of remission in rheumatoid arthritis for clinical trials.
Ann Rheum Dis. 2011;70:404–13.
3. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal
disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol.
2005;32:2016–24.
4. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G,
et al. Treating rheumatoid arthritis to target: recommendations of an
international task force. Ann Rheum Dis. 2010;69:631–7.
5. den Uyl D, Ter Wee M, Boers M, Kerstens P, Voskuyl A, Nurmohamed M,
et al. A non-inferiority trial of an attenuated combination strategy
(“COBRA-light”) compared to the original COBRA strategy: clinical results
after 26 weeks. Ann Rheum Dis. 2014;73:1071–8.
6. Ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van
Schaardenburg D, et al. Intensive combination treatment regimens,
including prednisolone, are effective in treating patients with early
rheumatoid arthritis regardless of additional etanercept: 1-year results of the
COBRA-light open-label, randomised, non-inferiority trial. Ann Rheum Dis.
2014;74:1233.
7. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission
and active disease in rheumatoid arthritis: defining criteria for disease
activity states. Arthritis Rheum. 2005;52:2625–36.
8. Ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA,
Markusse HM, et al. Randomised placebo-controlled study of stopping
second-line drugs in rheumatoid arthritis. Lancet. 1996;347:347–52.
9. van den Broek M, Klarenbeek NB, Dirven L, van Schaardenburg D, Hulsmans
HM, Kerstens PJ, et al. Discontinuation of infliximab and potential predictors
of persistent low disease activity in patients with early rheumatoid arthritis
and disease activity score-steered therapy: subanalysis of the BeSt study.
Ann Rheum Dis. 2011;70:1389–94.
10. Scott IC, Kingsley GH, Scott DL. Can we discontinue synthetic disease-
modifying anti-rheumatic drugs in rheumatoid arthritis? Clin Exp Rheumatol.
2013;31:S4–8.
11. Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA.
Progression of radiologic damage in patients with rheumatoid arthritis in
clinical remission. Arthritis Rheum. 2004;50:36–42.
12. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, et al.
An explanation for the apparent dissociation between clinical remission
and continued structural deterioration in rheumatoid arthritis. Arthritis
Rheum. 2008;58:2958–67.
13. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, et al.
Presence of significant synovitis in rheumatoid arthritis patients with
disease-modifying antirheumatic drug-induced clinical remission: evidence
from an imaging study may explain structural progression. Arthritis Rheum.
2006;54:3761–73.
14. Gent YY, Voskuyl AE, Kloet RW, van Schaardenburg D, Hoekstra OS,
Dijkmans BA, et al. Macrophage positron emission tomography imaging as
a biomarker for preclinical rheumatoid arthritis: findings of a prospective
pilot study. Arthritis Rheum. 2012;64:62–6.
15. Gent YY, Ahmadi N, Voskuyl AE, Hoetjes N, van Kuijk C, Britsemmer K, et al.
Detection of subclinical synovitis with macrophage targeting and positron
emission tomography in patients with rheumatoid arthritis without clinical
arthritis. J Rheumatol. 2014;41:2145–52.
16. Saleem B, Brown AK, Quinn M, Karim Z, Hensor EM, Conaghan P, et al. Can
flare be predicted in DMARD treated RA patients in remission, and is it
important? A cohort study. Ann Rheum Dis. 2012;71:1316–21.
17. Foltz V, Gandjbakhch F, Etchepare F, Rosenberg C, Tanguy ML, Rozenberg S,
et al. Power Doppler ultrasound, but not low-field magnetic resonance
imaging, predicts relapse and radiographic disease progression in
rheumatoid arthritis patients with low levels of disease activity. Arthritis
Rheum. 2012;64:67–76.
18. McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, et al.
Magnetic resonance imaging of the wrist in early rheumatoid arthritis
reveals progression of erosions despite clinical improvement. Ann Rheum
Dis. 1999;58:156–63.
19. Haavardsholm EA, Boyesen P, Ostergaard M, Schildvold A, Kvien TK. Magnetic
resonance imaging findings in 84 patients with early rheumatoid arthritis:
bone marrow oedema predicts erosive progression. Ann Rheum Dis.
2008;67:794–800.
20. Hetland ML, Ejbjerg B, Horslev-Petersen K, Jacobsen S, Vestergaard A, Jurik
AG, et al. MRI bone oedema is the strongest predictor of subsequent
radiographic progression in early rheumatoid arthritis. Results from a 2-year
randomised controlled trial (CIMESTRA). Ann Rheum Dis. 2009;68:384–90.
21. Haavardsholm EA, Gandjbakhch F, Conaghan P, Ejbjerg B, Foltz V, Brown A,
et al. Towards imaging remission: determining a MRI inflammatory activity
acceptable state in rheumatoid arthritis. Ann Rheum Dis. 2012;71 Suppl 3:149.
22. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, et al.
World Health Organization and International League of Associations for
Rheumatology core endpoints for symptom modifying antirheumatic drugs
in rheumatoid arthritis clinical trials. J Rheumatol Suppl. 1994;41:86–9.
23. van der Heijde DM, van’t Hof M, van Riel PL, van de Putte LB. Development
of a disease activity score based on judgment in clinical practice by
rheumatologists. J Rheumatol. 1993;20:579–81.
24. Ostergaard M, Peterfy C, Conaghan P, McQueen F, Bird P, Ejbjerg B, et al.
OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies.
Core set of MRI acquisitions, joint pathology definitions, and the OMERACT
RA-MRI scoring system. J Rheumatol. 2003;30:1385–6.
25. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al.
American College of Rheumatology/European League Against Rheumatism
provisional definition of remission in rheumatoid arthritis for clinical trials.
Arthritis Rheum. 2011;63:573–86.
26. Gandjbakhch F, Conaghan PG, Ejbjerg B, Haavardsholm EA, Foltz V, Brown
AK, et al. Synovitis and osteitis are very frequent in rheumatoid arthritis
clinical remission: results from an MRI study of 294 patients in clinical
remission or low disease activity state. J Rheumatol. 2011;38:2039–44.
27. Gent YY, Ter Wee MM, Ahmadi N, Van KC, Voskuyl AE, van der Laken CJ,
et al. Three-year clinical outcome following baseline magnetic resonance
imaging in anti-citrullinated protein antibody-positive arthralgia patients:
an exploratory study. Arthritis Rheumatol. 2014;66:2909–10.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gent et al. Arthritis Research & Therapy  (2015) 17:266 Page 6 of 6
